Differential role of MACC1 expression and its regulation of the HGF/c‑Met pathway between breast and colorectal cancer

Sueta,Aiko; Yamamoto,Yutaka; Yamamoto‑Ibusuki,Mutsuko; Hayashi,Mitsuhiro; Takeshita,Takashi; Yamamoto,Satoko; Omoto,Yoko; Iwase,Hirotaka

doi:10.3892/ijo.2015.2907

Differential role of MACC1 expression and its regulation of the HGF/c‑Met pathway between breast and colorectal cancer

Authors:
- Aiko Sueta
- Yutaka Yamamoto
- Mutsuko Yamamoto‑Ibusuki
- Mitsuhiro Hayashi
- Takashi Takeshita
- Satoko Yamamoto
- Yoko Omoto
- Hirotaka Iwase
View Affiliations

Affiliations: Department of Breast and Endocrine Surgery, Kumamoto University Graduate School of Medical Sciences, Kumamoto 860‑8556, Japan
Published online on: February 25, 2015 https://doi.org/10.3892/ijo.2015.2907
Pages: 2143-2153

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The newly identified gene, metastasis‑associated in colon cancer 1 (MACC1), is suggested to be a transcriptional regulator of c‑Met, leading to cancer progression in colorectal cancer. To date however, little is known of the role of MACC1 in breast cancer. In a series of 300 breast cancer patients, we analyzed the association of MACC1 mRNA and protein expression with breast cancer survival using Cox proportional hazard models. In an in vitro study, we evaluated activities of c‑Met protein after transfection with a MACC1‑harboring plasmid as well as the binding ability of MACC1 to the c‑Met promoter using a chromatin immunoprecipitation (ChIP) assay. In survival analyses, reduced MACC1 expression was associated with patient mortality. MACC1 expression was an independent prognostic factor in multivariate analysis. In the cell lines tested, MACC1 expression was much higher in colorectal than in breast cancer cells. After cells were transfected with MACC1, c‑Met expression was not induced in MCF7 cells, whereas corresponding c‑Met expression was upregulated in SW480 cells. Further, SW480 cells transfected with MACC1 showed enhanced migratory ability, whereas in MDA‑MB‑231 cells, transfection of MACC1 had no impact on this ability. In ChIP assay, the binding of MACC1 to the c‑Met promoter was suggested in SW480 cells, but not in MCF7 cells. In conclusion, our findings provide some novel insights into the role of MACC1 in breast cancer, indicating that it plays different roles in breast and several other cancers. There is a possibility that MACC1 does not modulate the transcriptional role of c‑Met signaling in breast cancer.

View Figures

View References

1	Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W and Sobue T; Japan Cancer Surveillance Research Group. Cancer incidence and incidence rates in Japan in 2005: based on data from 12 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 41:139–147. 2011. View Article : Google Scholar
2	Parker JS, Mullins M, Cheang MC, et al: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 27:1160–1167. 2009. View Article : Google Scholar : PubMed/NCBI
3	van’t Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:530–536. 2002. View Article : Google Scholar
4	Cronin M, Sangli C, Liu ML, Pho M, Dutta D, Nguyen A, Jeong J, Wu J, Langone KC and Watson D: Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem. 53:1084–1091. 2007. View Article : Google Scholar : PubMed/NCBI
5	Sierra JR and Tsao MS: c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol. 3(Suppl 1): S21–S35. 2011. View Article : Google Scholar : PubMed/NCBI
6	Turner N, Lambros MB, Horlings HM, et al: Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene. 29:2013–2023. 2010. View Article : Google Scholar : PubMed/NCBI
7	Turner N, Tutt A and Ashworth A: Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer. 4:814–819. 2004. View Article : Google Scholar : PubMed/NCBI
8	Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I, Birchmeier W and Schlag PM: MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med. 15:59–67. 2009. View Article : Google Scholar
9	Boardman LA: Overexpression of MACC1 leads to downstream activation of HGF/MET and potentiates metastasis and recurrence of colorectal cancer. Genome Med. 1:362009. View Article : Google Scholar : PubMed/NCBI
10	Qiu J, Huang P, Liu Q, Hong J, Li B, Lu C, Wang L, Wang J and Yuan Y: Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. J Transl Med. 9:1662011. View Article : Google Scholar : PubMed/NCBI
11	Wang L, Wu Y, Lin L, et al: Metastasis-associated in colon cancer-1 upregulation predicts a poor prognosis of gastric cancer, and promotes tumor cell proliferation and invasion. Int J Cancer. 133:1419–1430. 2013. View Article : Google Scholar : PubMed/NCBI
12	Zhang R, Shi H, Chen Z, Wu Q, Ren F and Huang H: Effects of metastasis-associated in colon cancer 1 inhibition by small hairpin RNA on ovarian carcinoma OVCAR-3 cells. J Exp Clin Cancer Res. 30:832011. View Article : Google Scholar : PubMed/NCBI
13	Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT and Salgia R: Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev. 13:41–59. 2002. View Article : Google Scholar
14	Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF and Aaronson SA: Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 251:802–804. 1991. View Article : Google Scholar : PubMed/NCBI
15	Di Renzo MF, Olivero M, Giacomini A, et al: Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res. 1:147–154. 1995.PubMed/NCBI
16	Humphrey PA, Zhu X, Zarnegar R, Swanson PE, Ratliff TL, Vollmer RT and Day ML: Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol. 147:386–396. 1995.PubMed/NCBI
17	Amemiya H, Kono K, Itakura J, Tang RF, Takahashi A, An FQ, Kamei S, Iizuka H, Fujii H and Matsumoto Y: c-Met expression in gastric cancer with liver metastasis. Oncology. 63:286–296. 2002. View Article : Google Scholar : PubMed/NCBI
18	Jin L, Fuchs A, Schnitt SJ, Yao Y, Joseph A, Lamszus K, Park M, Goldberg ID and Rosen EM: Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer. 79:749–760. 1997. View Article : Google Scholar : PubMed/NCBI
19	Camp RL, Rimm EB and Rimm DL: Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer. 86:2259–2265. 1999. View Article : Google Scholar : PubMed/NCBI
20	Lengyel E, Prechtel D, Resau JH, et al: C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer. 113:678–682. 2005. View Article : Google Scholar
21	Stein U, Smith J, Walther W and Arlt F: MACC1 controls Met: what a difference an Sp1 site makes. Cell Cycle. 8:2467–2469. 2009. View Article : Google Scholar : PubMed/NCBI
22	Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B and Senn HJ; Panel members. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 22:1736–1747. 2011. View Article : Google Scholar : PubMed/NCBI
23	Yamamoto S, Ibusuki M, Yamamoto Y, Fu P, Fujiwara S, Murakami K and Iwase H: Clinical relevance of Ki67 gene expression analysis using formalin-fixed paraffin-embedded breast cancer specimens. Breast Cancer. 20:262–270. 2013. View Article : Google Scholar
24	Dowsett M, Nielsen TO, A’Hern R, et al; International Ki-67 in Breast Cancer Working Group. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 103:1656–1664. 2011. View Article : Google Scholar : PubMed/NCBI
25	Hartzell DD, Trinklein ND, Mendez J, Murphy N, Aldred SF, Wood K and Urh M: A functional analysis of the CREB signaling pathway using HaloCHIP-chip and high throughput reporter assays. BMC Genomics. 10:4972009. View Article : Google Scholar : PubMed/NCBI
26	Huang Y, Zhang H, Cai J, Fang L, Wu J, Ye C, Zhu X and Li M: Overexpression of MACC1 and its significance in human breast cancer progression. Cell Biosci. 3:162013. View Article : Google Scholar : PubMed/NCBI
27	Law JH, Habibi G, Hu K, et al: Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res. 68:10238–10246. 2008. View Article : Google Scholar : PubMed/NCBI
28	Railo MJ, von Smitten K and Pekonen F: The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients. Eur J Cancer. 30A:307–311. 1994. View Article : Google Scholar : PubMed/NCBI
29	Shin A, Ren Z, Shu XO, Cai Q, Gao YT and Zheng W: Expression patterns of insulin-like growth factor 1 (IGF-I) and its receptor in mammary tissues and their associations with breast cancer survival. Breast Cancer Res Treat. 105:55–61. 2007. View Article : Google Scholar
30	Papa V, Gliozzo B, Clark GM, McGuire WL, Moore D, Fujita-Yamaguchi Y, Vigneri R, Goldfine ID and Pezzino V: Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res. 53:3736–3740. 1993.PubMed/NCBI
31	Stein U, Dahlmann M and Walther W: MACC1 - more than metastasis? Facts and predictions about a novel gene. J Mol Med Berl. 88:11–18. 2010. View Article : Google Scholar
32	http://www.ncbi.nlm.nih.gov/UniGene/ESTProfileViewer.cgi?uglist=Hs.598388.
33	Kang JY, Dolled-Filhart M, Ocal IT, Singh B, Lin CY, Dickson RB, Rimm DL and Camp RL: Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res. 63:1101–1105. 2003.PubMed/NCBI
34	Boccaccio C and Comoglio PM: Invasive growth: A MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer. 6:637–645. 2006. View Article : Google Scholar : PubMed/NCBI
35	Peschard P and Park M: From Tpr-Met to Met, tumorigenesis and tubes. Oncogene. 26:1276–1285. 2007. View Article : Google Scholar : PubMed/NCBI
36	Trusolino L, Bertotti A and Comoglio PM: MET signalling: Principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol. 11:834–848. 2010. View Article : Google Scholar : PubMed/NCBI
37	Ghoussoub RA, Dillon DA, D’Aquila T, Rimm EB, Fearon ER and Rimm DL: Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer. 82:1513–1520. 1998. View Article : Google Scholar : PubMed/NCBI
38	Hiscox S, Jordan NJ, Jiang W, Harper M, McClelland R, Smith C and Nicholson RI: Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: Implications for tumour-stroma interactions. Endocr Relat Cancer. 13:1085–1099. 2006. View Article : Google Scholar : PubMed/NCBI
39	Shattuck DL, Miller JK, Carraway KL III and Sweeney C: Met receptor contributes to trastuzumab resistance of Her2-over-expressing breast cancer cells. Cancer Res. 68:1471–1477. 2008. View Article : Google Scholar : PubMed/NCBI
40	Minuti G, Cappuzzo F, Duchnowska R, et al: Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer. Br J Cancer. 107:793–799. 2012. View Article : Google Scholar : PubMed/NCBI
41	Jiang WG, Martin TA, Parr C, Davies G, Matsumoto K and Nakamura T: Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol. 53:35–69. 2005. View Article : Google Scholar
42	Maemura M, Iino Y, Yokoe T, Horiguchi J, Takei H, Koibuchi Y, Horii Y, Takeyoshi I, Ohwada S and Morishita Y: Serum concentration of hepatocyte growth factor in patients with metastatic breast cancer. Cancer Lett. 126:215–220. 1998. View Article : Google Scholar : PubMed/NCBI
43	Arlt F and Stein U: Colon cancer metastasis: MACC1 and Met as metastatic pacemakers. Int J Biochem Cell Biol. 41:2356–2359. 2009. View Article : Google Scholar : PubMed/NCBI
44	Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S and Comoglio PM: Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 3:347–361. 2003. View Article : Google Scholar : PubMed/NCBI
45	Ipsaro JJ, Huang L and Mondragón A: Structures of the spectrin-ankyrin interaction binding domains. Blood. 113:5385–5393. 2009. View Article : Google Scholar : PubMed/NCBI
46	Kadonaga JT, Jones KA and Tjian R: Promoter-specific activation of RNA polymerase II transcription by Sp1. Trends Biochem Sci. 11:20–23. 1986. View Article : Google Scholar